A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to experimental motion
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Seliforant (Primary) ; Meclozine
- Indications Vertigo
- Focus Pharmacodynamics
- Sponsors Sensorion
- 12 May 2019 Status changed from active, no longer recruiting to completed.
- 14 Dec 2018 Top-line results presented in a Sensorion media release.
- 27 Nov 2018 According to a Sensorion media release, subject enrolment and dosing has been completed in this trial.